Sponsored By

Podcast: Cytiva cites COVID as driver for biopharma resilience

Dan Stanton

July 15, 2022

Emmanuel Ligner, CEO of self-described bioprocess “critical actor” Cytiva talks us through the changing biomanufacturing landscape and unveils his firm’s sustainability report in the latest BioProcess Insider Expression Platform podcast.

In 2021, Cytiva launched a survey measuring industry’s confidence in the biopharma space. Focusing across five pillars – supply chain resilience, talent pool, the R&D ecosystem, manufacturing agility, and government policy and regulation – the Biopharma Resilience Index averaged an overall score of 6.6 out of 10 in 2021.

cytiva-bio-300x225.jpg

Feedback from 2022’s survey showed “COVID was a wake-up call,” Emmanuel Ligner told us at BIO in San Diego last month. “Suddenly people realized we need to do something different; we need to pay more attention to the supply chain. We also saw governments reacting very well in many countries, and that was a very positive thing. Overall, 63% said [COVID] was a wakeup call and I think that was good for the industry.”

Ligner also spoke about his firm’s sustainability efforts, citing a recently published report on the issue.

Listen below, or download at Spotify, Amazon, iTunes, or wherever you get your podcasts.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.